We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
US regulators have accepted for review a targeted, Gram-positive investigational antibiotic developed by UK biopharma Motif Bio for the treatment of acute bacterial skin and skin structure infections (ABSSSI).